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Abstract: Skin and skin structure infections (SSSIs) are a common diagnosis encountered 
by ambulatory and inpatient practitioners across the country. As the SSSIs become more 
complicated, they require increased health care resources and often involve hospitalization and 
intravenous antimicrobials. Complicated SSSIs are caused by a variety of pathogens, including 
Gram-positive,  Gram-negative,  and  anerobic  bacteria.  Empiric  broad-spectrum  antibiotic 
coverage is warranted, taking into account area disease-state epidemiology and antimicrobial 
susceptibility data. Telavancin is an antimicrobial agent with a broad Gram-positive spectrum 
of activity which was recently approved for the treatment of SSSIs. It may especially benefit 
patients with resistant organisms, such as methicillin-resistant Staphylococcus aureus. This 
article  reviews  telavancin  and  its  pharmacology,  efficacy,  and  safety  data  to  enhance  the 
practitioner’s knowledge base on the appropriateness of telavancin for the treatment of SSSIs.
Keywords: skin and skin structure infections, telavancin, methicillin-resistant Staphylococcus 
aureus
Introduction
Skin and skin structure infections (SSSIs) are a frequent indication for hospitalization 
and antibiotic treatment in the US.1 More specifically, they can be further delineated 
as uncomplicated or complicated SSSIs, based on the degree of tissue involvement.2 
Uncomplicated SSSIs include superficial cellulitis, folliculitis, furunculosis, simple 
abscesses, and minor wound infections. Uncomplicated SSSIs involving the epidermis 
and dermis usually respond to a course of enteral antibiotics with or without 
incision and drainage. Complicated SSSIs involve invasion of deeper structures 
such as subcutaneous tissue, fascia, or muscle. They potentially require significant 
surgical interventions, especially in patients demonstrating a poor response to initial 
antibiotic therapy secondary to underlying disease states, such as diabetes mellitus, 
vascular insufficiency, sensory neuropathies, obesity, poor hygiene, or certain 
immunodeficiencies. Complicated SSSIs include complicated skin abscesses, infected 
burns and ulcers, and deep space wound infections.3
Various bacteria may be involved in SSSIs, depending upon the disease process, 
clinical presentation, and environment. Beta-hemolytic streptococci and Staphylococcus 
aureus are the most common isolated pathogens. However, β-hemolytic streptococci 
are likely underrepresented as a pathogen because superficial cellulitis does not 
require hospitalization, and adequate cultures are difficult and unnecessary to attain 
in less complicated infections. The most common pathogen, S. aureus, is recognized 
in 44% of SSSIs in North America (Figure 1).4 However, as the SSSI becomes more Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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complicated, the incidences of Gram-negative and anerobic 
microorganisms increase.
Over the last 20 years, there has been a dramatic increase 
in methicillin-resistant S. aureus (MRSA) in patients with 
no known contact with health care institutions or other 
risk factors for acquiring hospital-associated MRSA; these 
strains are referred to as community-associated MRSA.5 
Community-associated MRSA, a genetically unique organism 
which carries the gene that encodes Panton–Valentine 
leukocidin, a deadly exotoxin, is commonly associated with 
SSSI acquired in the outpatient setting.6 This exotoxin is the 
key characteristic associated with community-associated 
MRSA, which causes necrosis of the skin and abscess forma-
tion.7,8 This directly impacts empiric antimicrobial choices 
in the outpatient setting because community-associated 
MRSA is not susceptible to cephalosporins (excluding 
ceftobiprole and ceftaroline) and anti-staphylococcal 
penicillins. However, community-associated MRSA does 
maintain susceptibility to enteral antimicrobials including 
tetracyclines, trimethoprim-sulfamethoxazole, clindamycin, 
and linezolid.3 Patients with complicated SSSI requiring 
hospitalization are routinely started on intravenous broad-
spectrum antimicrobial agents which maintain activity against 
both community-associated MRSA and hospital-  associated 
MRSA, such as   vancomycin, linezolid,   daptomycin, 
tigecycline, and quinupristin/  dalfopristin (Pfizer, Cubist, 
Wyeth, King). These intravenous   antimicrobial agents should 
then be de-escalated to appropriate enteral therapy based 
on culture and sensitivity results. As of   September 2009, 
another intravenous antimicrobial agent with activity against 
MRSA has become available, ie, telavancin.9 Identification 
of medical literature on the role of telavancin in the treat-
ment of SSSI was done through an Ovid Medline® literature 
search.
Pharmacology
Telavancin is a lipoglycopeptide antibiotic with a dual 
mechanism of action. Like other glycopeptides, telavancin 
inhibits bacterial cell wall synthesis by binding to the 
terminal D-Ala-D-Ala of newly formed peptidoglycan 
chains. This prevents crosslinking and polymerization of 
the cell wall. Despite having a fivefold reduced affinity 
for the D-Ala-D-Ala moiety, telavancin is 10 times more 
potent than vancomycin in the inhibition of peptidoglycan 
synthesis. Telavancin also increases bacterial cell membrane 
permeability which leads to efflux of intracellular adenosine-
5′-triphosphate and potassium. This quickly decreases 
the cell membrane potential and gives telavancin its rapid 
concentration-dependent bactericidal activity.10
Telavancin contains the same structural core as 
vancomycin, with two significant differences. First, a 
lipophilic side chain on the vancosamine sugar extends the 
serum half-life and increases antimicrobial activity against 
resistant S. aureus and Enterococcus species. Second, 
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Figure 1 Most common bacterial pathogens producing skin and soft tissue infections in North America (1998–2004). 
Copyright © 2007. Adapted with permission from Moet GJ, Jones RN, Biedenbach DJ, Stilwel MG, Fritsche TR. Contemporary causes of skin and soft tissue infection in North 
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a polar phophonomethyl aminomethyl group enhances tissue 
penetration, but reduces the serum half-life of the compound 
by promoting renal clearance.11 The net result is a prolonged 
half-life as compared with vancomycin.
Pharmacokinetics
Telavancin is only available as an intravenous formulation, 
because glycopeptides have poor systemic absorption 
following enteral administration. When telavancin infuses 
over 30–120 minutes as single doses of 1–12.5 mg/kg or 
multiple once-daily doses of 7.5–15 mg/kg, it exhibits 
linear pharmacokinetics and achieves steady state by the 
third daily dose, as demonstrated in a two-part, randomized, 
double-blind, placebo-controlled, dose-escalation study in 
54 healthy male volunteers over a period of seven days.12 
Another study assessed the pharmacokinetic parameters 
utilizing a randomized, double-blind, parallel-group, gender-
stratified, two-dose method in 79 adult subjects over a 
period of three days. Dose-proportional increases in mean 
peak serum concentrations and total systemic exposure 
were observed, similar to the results from the first study.13 
A third study observed healthy young adults receiving 
single (n = 42) or multiple doses (n = 36) of telavancin 
10 mg/kg infused over 60 minutes. The mean peak serum 
concentrations were 93.6 and 108 µg/mL and the area 
under the serum concentration curves were 666 µg⋅hr/mL 
and 780 µg⋅hr/mL, respectively.9 It exhibits a steady-state 
volume of distribution of about 0.1 L/kg and is 90%–93% 
bound by plasma proteins. The terminal half-life of tela-
vancin is about 7–9 hours, and it displays a postantibiotic 
effect of 4–6 hours. These characteristics allow for once-
daily dosing of telavancin. Renal clearance of telavancin 
accounts for 65%–72% of plasma clearance, and two-thirds 
of the total dose is excreted in the urine unchanged.13 The 
metabolism of telavancin has not been fully described, but it 
does not have a clinically relevant effect on the cytochrome 
p450 enzyme systems.14
In patients with normal hepatic and renal   function, the 
recommended dose of telavancin is 10 mg/kg intravenously 
every 24 hours. There are no gender- or age-related 
differences in the plasma pharmacokinetics of telavan-
cin.13 Telavancin has not been studied in pediatric patients. 
Dose adjustment of telavancin is recommended for renal 
impairment because of increased drug accumulation 
with worsening creatinine clearance and the potential for 
increased accumulation of hydroxypropyl-beta-  cyclodextrin, 
a   solubilizing agent present in the intravenous formulation.9 
In patients with creatinine clearance of 30–50 mL/min, 
75% of the total dose should be   administered at the 
same dosing interval. For those with creatinine clearance 
of 10–29 mL/min, the full dose should be given every 
48 hours.11 There are no specific dosing recommendations 
for telavancin in patients with end-stage renal disease, 
on hemodialysis, or on continuous renal replacement 
therapy, because of limited patient populations. However, 
in Phase III studies, patients on hemodialysis received 
telavancin 10 mg/kg every 48 hours. No supplemental 
dose was administered after dialysis, given that telavancin 
is poorly cleared by dialysis. Continuous hemodialysis and 
continuous hemofiltration have been shown to significantly 
clear telavancin in an in vitro model.15
Spectrum of activity
Telavancin demonstrates broad in vitro activity against a 
number of Gram-positive organisms, including those resistant 
to other antimicrobial agents such as MRSA (Table 1). When 
assessing the minimum inhibitory   concentrations necessary 
to inhibit 90% (MIC90) of the target bacterial strains, 
telavancin demonstrates excellent activity against S. aureus 
(including MRSA isolates). For both methicillin-susceptible 
S. aureus and MRSA, MIC90 breakpoints were in the range 
0.25–1 mg/L. However, the telavancin MIC90 was slightly ele-
vated in glycopeptide-intermediate staphylococcal species. At 
1 mg/L, telavancin also possesses excellent streptococci cover-
age, including multidrug-resistant strains. Multidrug-resistant 
and penicillin-susceptible Streptococcus pneumoniae both 
have MIC90 values of 0.03 mg/L. Beta-hemolytic strepto-
cocci and viridans streptococci have low MIC90 values in 
the ranges 0.001–0.25 mg/L and 0.001–1 mg/L, respectively. 
Vancomycin-susceptible Enterococcus faecalis and Entero-
coccus faecium are also susceptible to telavancin, with MIC90 
breakpoints of #1 mg/L. However, when the Enterococcus 
strains are resistant to vancomycin, the MIC90 values are 
elevated, with E. faecalis in the range 4–16 mg/L and E. 
faecium in the range 2–8 mg/L. Telavancin is also effective 
against anerobic Gram-positive organisms and Cornyebac-
terium species. Telavancin demonstrates no activity against 
  Gram-negative organisms.16
Efficacy of telavancin  
in clinical trials
Two Phase II and two Phase III clinical trials were submitted to 
the US Food and Drug Administration (FDA) for approval of 
telavancin. The first Phase II trial, conducted by the FAST study 
group, evaluated the efficacy of   telavancin for complicated Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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SSSIs caused by Gram-positive bacteria.17 In this double-blind, 
parallel-group, multinational clinical trial, 167 patients with 
suspected or confirmed Gram-positive complicated SSSI, 
were randomized in a 1:1 ratio to receive 7.5 mg/kg telavancin 
intravenously once a day or standard therapy. Standard therapy 
was defined as intravenous vancomycin 1 g every 12 hours, 
nafcillin or oxacillin 2 g every six hours, or cloxacillin 0.5–1 g 
every six hours. Vancomycin monitoring and dosing varied 
according to the standards at each institution. Therapy was 
continued for 4–14 days depending on location and severity of 
infection. The primary endpoint was to assess clinical response 
in the clinically evaluable population, with cure defined as 
the resolution of clinically significant signs and symptoms 
of complicated SSSI and if there was eradication of a patho-
gen in the microbiologically evaluable patients at the test of 
cure evaluation occurring 7–14 days after the last dose was 
administered. Patient characteristics were similar between the 
treatment groups at baseline, and pathogens were isolated in 
81% of the total treated population. Of the pathogens isolated, 
53% were S. aureus (of which 49% were methicillin-resistant), 
22% were Gram-negative bacteria, and 12% were nonen-
terococcal streptococci. In the total randomized population, 
the primary endpoint was achieved in 79% of patients in the 
telavancin group and 80% of patients in the standard therapy 
group (P = 0.53). In patients with S. aureus infection, cure was 
attained in 80% of those in the telavancin group and 77% in 
the standard therapy group (P = 0.80). In MRSA infections, 
the telavancin and standard therapy groups had 82% and 69% 
cure rates, respectively (P = 1.00). The differences in cure rates 
between treatment groups were not clinically or statistically 
significant. Treatment with telavancin was associated with four 
serious adverse events, compared with nine events in the stan-
dard therapy group. Discontinuation of therapy due to adverse 
events occurred at a rate of 5% in both treatment groups.
Another Phase II trial was conducted by the FAST 
2 study group.18 This double-blind, parallel-group, mul-
tinational clinical trial randomized 195 patients to either 
telavancin 10 mg/kg intravenously once a day or standard 
therapy. Standard therapy and therapy length was defined the 
same as for the previous FAST trial. Baseline patient char-
acteristics were similar between treatment groups. At least 
one pathogen was identified in 82% of the study population. 
Of the pathogens isolated, 52% were S. aureus, 19% were 
Gram-negative bacteria, and 16% were nonenterococcal 
streptococci. In the total randomized population, cure was 
achieved by 82% of patients in the telavancin group and 85% 
of patients in the standard therapy group (P = 0.37). Among 
patients with S. aureus isolates, cure was achieved by 96% in 
the telavancin group and 90% in the standard therapy group 
(P = 0.36). Cure rates for both treatment groups in patients 
with MRSA was the same as those observed for S. aureus. 
These results were not   statistically significant between 
treatment groups. Treatment with telavancin was associated 
with a 6% rate of serious adverse events, compared with a 
4% rate in the standard therapy group. Adverse events led 
to discontinuation of therapy in 6% of patients treated with 
telavancin and 3% in the standard therapy group.
The only Phase III trials evaluating telavancin for 
complicated SSSI, with abscess and cellulitis being the 
most common baseline diagnoses, were the ATLAS 1 and 
Table 1 Activity of telavancin and other comparators for Gram-positive clinical isolates
Organism Agent and MIC90 (μg/mL)
Telavancin Vancomycin Linezolid Daptomycin Quinipristin- 
dalfopristin
MSSA 0.5 1 2 0.5 0.5
MRSA 0.25 1 2 0.5 0.5
E. faecalis vancomycin- 
susceptible
1 2 0.25 1 1
E. faecalis harboring  
van A
16 .512 2 1 n/a
E. faecium vancomycin  
susceptible
0.25 1 2 4 2
E. faecium harboring  
van A
8 512 2 4 1
E. faecium harboring  
van B
2 0.5 1 4 4
Abbreviations: MSSA, methicillin-susceptible Staphylococcus aureus; MRSA, methicillin-resistant Staphylococcus aureus; MIC90, minimum inhibitory concentration. Copyright © 
2008. Adapted with permission from Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. Comparative surveillance study of telavancin activity against 
recently collected gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother. 2008;52:2383–2388.Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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ATLAS 2 studies. The results of the two trials were combined 
in a prespecified pooled analysis.19 These two parallel, double-
blind, multinational, noninferior clinical trials randomized 
a total of 1867 patients to receive telavancin 10 mg/kg 
intravenously once a day or vancomycin 1 g every 12 hours 
(which could be dose-adjusted based upon the standards at 
each institution). Therapy was administered for 7–14 days 
depending on severity and location of infection. The primary 
endpoint was test of cure in all-treated and clinically evaluable 
populations. The clinically nonevaluable population was 
defined as those patients who were lost to follow-up, had 
withdrawn consent, died, had an indeterminate response to the 
antimicrobials, received prohibited antimicrobials, or received 
less than seven days of antimicrobials. A pathogen was cul-
tured in 74% of all treated patients, of which 83% were identi-
fied as S. aureus. Of the S. aureus cultures, 52% were MRSA. 
In the population considered clinically evaluable, clinical cure 
occurred in 88.3% of those in the telavancin group and 87.1% 
of those in the vancomycin group (95% confidence interval 
[CI]: -2.1–4.6). Among patients with MRSA cultures, cure 
was achieved in 90.6% of those in the telavancin group and 
84.4% of those in the vancomycin group (95% CI: -1.1–9.3). 
In both trials, the mean length of therapy was about one day 
shorter with telavancin than with vancomycin. Adverse events 
occurred in 7% of those treated with telavancin and 4% of 
those treated with vancomycin. Therapy was discontinued 
due to serious adverse events (mostly commonly a cardiac, 
respiratory, or infectious event) in 8% of those in the tela-
vancin group and in 6% of those in the vancomycin group. 
Additional detail regarding adverse drug reactions is provided 
in the safety section of this review.
In a retrospective subanalysis of the ATLAS trials, the 
efficacy of telavancin for surgical site infections was assessed 
in 194 patients (telavancin n = 101, vancomycin n = 93). 
A Gram-positive organism was identified in every patient 
included in the analysis. S. aureus was isolated in 49% of 
patients (n = 95) and MRSA was identified in 22% of all patients 
(n = 42). The median length of therapy was 10 days in both 
treatment groups. The clinical cure rate was similar between 
telavancin and vancomycin (77.2% versus 69.9%, respectively) 
in the all-treated population, and not statistically significant 
(95% CI: -5.1–24.2). Among patients infected with MRSA, 
the cure rate was 85.7% in the telavancin group and 71.4% in 
the vancomycin group. The differences in cure rates between 
treatment groups did not reach statistical significance (95% 
CI: -11.3–37.4). Therapy was discontinued due to adverse 
events in 12% of patients in the telavancin group and 10% of 
patients in the vancomycin group. The adverse events that led to 
discontinuation occurred in ,2% of either treatment group.20
Safety
Adverse events attributed to treatment in the ATLAS 1 and 
2 Phase III trials were assessed in 929 patients treated with 
telavancin and 938 patients treated with vancomycin. Nausea 
(15% versus 27%), taste disturbance described as “soapy” 
or metallic (33% versus 7%), insomnia (10% versus 9%), 
foamy urine (13% versus 3%), and headache (14% versus 
13%) were the most common mild adverse events, respec-
tively. In the FAST 2 trial, hypokalemia occurred more 
often in the telavancin group than in the standard therapy 
group (7% of patients versus 0% respectively, P = 0.01), 
but this was not as apparent in the ATLAS 1 or 2 trials. An 
increase in serum creatinine was observed more frequently 
in the telavancin-treated group than in the control therapy 
group in all trials, although this difference did not reach 
statistical significance. This increase was usually mild and 
most cases were reversible after discontinuation of therapy. 
Higher renal adverse events were seen in patients greater than 
65 years of age, comorbidities affecting kidney function, or 
concomitant medications that can affect kidney function. 
Electrocardiographic data from all trials demonstrated a 
prolongation in QTc (Fridericia corrected) interval associated 
with telavancin treatment. This prolongation was 6.4 msec 
and 12.5 msec in the FAST and FAST 2 trials, respectively, 
which is comparable with the QTc prolongation caused by 
quinolone antibiotics.17,18 Further information was gathered 
in a separate study of 160 patients randomized to receive 
intravenous telavancin 7.5 mg/kg, 15 mg/kg, moxifloxacin 
400 mg, or placebo. QTc intervals of 4.1 msec (P = 0.036), 
4.5 msec (P = 0.027), and 9.2 msec (P , 0.001) were noted 
accordingly. However, no cardiac adverse events were 
reported to be caused by this QTc prolongation.21
Telavancin shares much of the same structure as vanco-
mycin, and as a result has many of the same precautions.9 The 
cross-sensitivity of telavancin with vancomycin is unknown 
because patients with a documented allergy to vancomycin 
were excluded from clinical trials; consequently it should 
be avoided in patients with documented hypersensitivity or 
intolerance to vancomycin. Telavancin has been associated 
with infusion-related reactions like other glycopeptide 
antimicrobials, such as red man syndrome-like reactions, 
including flushing of the upper body, urticaria, pruritis, or 
rash.12 Therefore, it should be administered over 60 minutes 
or even slower or stopped to cease any of these reactions. Clinical, Cosmetic and Investigational Dermatology 2010:3 submit your manuscript | www.dovepress.com
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Telavancin is listed as pregnancy category C, meaning that 
animal data suggest telavancin may be teratogenic in humans. 
A black box warning states that women of child-bearing age 
should have a serum pregnancy test prior to the initiation 
of telavancin, and used only if the benefits outweigh the 
risks. A pregnancy registry has been developed to monitor 
outcomes in patients exposed to telavancin during pregnancy 
because there are no human pregnancy data.9 Astellas has 
also developed a risk evaluation and mitigation system for 
telavancin in order to inform all involved prescribing and 
dispensing health care professionals of its potential toxicity 
in pregnancy. Health care professional letters were distributed 
prior to commercial distribution, and then again at six months, 
12 months, and 24 months after product approval.22
Telavancin does not interfere with the coagulation cascade, 
but it can affect some tests that monitor coagulation when 
drawn within 18 hours of telavancin administration. Pro-
thrombin time, international normalized ratio, activated partial 
thromboplastin time, activated clotting time, and coagulation-
based Factor Xa tests have all been shown to be falsely elevated 
following telavancin infusion. Telavancin can bind to the 
artificial phospholipid surfaces added to common anticoagu-
lation tests, and interfere with the coagulation complexes to 
assemble on the surface of phospholipids and promote clotting 
in vitro. It is recommended by the manufacturer to draw these 
coagulation monitoring samples prior to the next telavancin 
dose administered so that there is minimal drug interference. 
There has been no evidence of increased bleeding risk, hyper-
coagulability, or effect on platelet aggregation.9
Discussion
In the contemporary drug arena, any new pharmaceutical 
coming to market must offer a clear advantage over the current 
standard of therapy to be incorporated into practice. Efficacy, 
safety, and cost are most often considered. Telavancin has dem-
onstrated efficacy for the treatment of SSSI caused by Gram-
positive bacteria, although it was not better than the standard 
of therapy. In clinical trials, patients treated with telavancin 
achieved a clinical cure one day earlier than standard therapy. 
This may allow for shorter hospital stays with telavancin. With 
the development of resistance to standard therapy, telavancin’s 
bactericidal activity may give it a therapeutic edge in the 
future for bacteria that are resistant to vancomycin. Telavancin 
currently only provides a modest improvement in efficacy 
compared with established Gram-positive antibiotics.
Given that telavancin has the same efficacy as standard 
therapy, determining its place in therapy should be based 
on side effect profile, administration issues, and cost. The 
once-daily dosing of telavancin provides an advantage 
over other established therapy which can be dosed two to 
four times a day. Unlike other glycopeptides, serum level 
  monitoring is not required for treatment with telavancin. Hav-
ing the same basic structure as vancomycin gives telavancin 
a similar side effect profile to that of vancomycin. Telavancin 
was associated with more nephrotoxicity, hypokalemia, and 
taste disturbances than vancomycin in clinical trials   making 
it a less promising option. It is not recommended to use 
telavancin in pregnant women, and caution is advised when 
using other medications that cause corrected QT interval pro-
longation. At current average wholesale pricing, telavancin is 
one of the most expensive options third only to daptomycin 
and intravenous linezolid (Table 2). Venous access must be 
maintained during treatment with telavancin because there 
is no enteral formulation of telavancin available.
Summary
Telavancin is an intravenously administered lipoglycopeptide 
that exhibits potent in vitro activity against most clinically 
significant Gram-positive bacteria, including MRSA and 
glycopeptide-intermediate staphylococcal species. A long 
half-life and post-antibiotic effect affords once-daily dosing 
of telavancin. Serum drug level monitoring is not required, 
although patients with reduced renal function do require dose 
adjustments. Telavancin was approved for the treatment of 
SSSI based on the results of two Phase II and two Phase III 
trials in which telavancin was found to be noninferior as 
compared with standard therapy. Telavancin displays a similar 
side effect profile compared with that of vancomycin, with 
the exception of higher rates of hypokalemia, creatinine 
elevation, and QTc prolongation. Although the approval of 
Table 2 Cost of common drugs for Gram-positive skin and soft 
tissue infections
Enteral Dose* Cost/day†
Cephalexin 500 mg 4 times a day $5.32
Clindamycin 300–600 mg q4–6 hrs $9.28
Dicloxacillin 500 mg 4 times a day $4.80
Linezolid 600 mg q12 hrs $183.95
Trimethoprim-  
sulfamethoxazole
1–2 double strength  
tablets q8–12 hrs
$1.76
Intravenous Dose* Cost/day†
Clindamycin 600 mg q8 hrs $12.00
Daptomycin 4–6 mg/kg/day $272.70
Linezolid 600 mg q12 hrs $240.20
Telavancin 10 mg/kg/day $186.00
Tigecycline 100 mg × 1, then 50 mg q12 hrs $147.00
vancomycin 15–20 mg/kg q8–12 hrs $13.48
Notes: *Reflects a standard regimen for the treatment of SSSI in adults. with normal 
renal and hepatic function. †Cost data is acquisition wholesale price.Clinical, Cosmetic and Investigational Dermatology
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telavancin allows for its use as an alternative for the treatment 
of SSSI caused by MRSA, glycopeptide-intermediate staphy-
lococci, and multidrug-resistant streptococci, its role for the 
treatment of vancomycin-resistant enterococci is limited due 
to elevated in vitro minimum inhibitory concentrations and 
lack of outcome data. Telavancin is likely a costly alternative 
to standard therapy. Consequently, its place in therapy has 
yet to be determined.
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